A study with three years of follow-up shows that the drug stays effective and safe for most, although 16% stopped getting treated with Dupixent, mainly because it was ineffective or caused side effects.
|Podcasts|January 26, 2022
Rodrigo Cerda, M.D.., M.P.H., of Independence Blue Cross in Philadelphia Discusses New Role and the Latest on Value-based Care, SDOH and Covid-19
Author(s)Peter Wehrwein, Briana Contreras
In this episode, Peter Wehrwein, managing editor of Managed Healthcare Executive, speaks with Dr. Rodrigo Cerda. Dr. Cerda has been recently promoted to the position of senior vice president of health services and chief medical officer of Independence Blue Cross in Philadelphia. He is also a member of Managed Healthcare Executive’s editorial advisory board. Peter and Dr. Cerda discuss his new role at the Independence Blue Cross, what it means to be a chief medical officer at an insurer these days, valued-based care, social determinants of health, and, of course, the pandemic.
Advertisement
To listen to more episodes featured on Tuning Into The C-Suite, visit us on
Advertisement
Related to this article
Heart disease became the leading cause of death among Hispanic adults in the U.S. in 2022, and a new American Heart Association statement says risk varies by heritage, with gaps in coverage, language and food access adding to the burden.
A five-session course of transcranial magnetic stimulation (TMS) improved processing speed in people with schizophrenia, a cognitive domain that is among the most severely affected in patients,
National Alliance names Jenny Goins interim CEO after former leader’s arrest; details emerge on charges, firing timeline, and impact on healthcare policy circles.
Only 19% use AI predictive models in cancer care despite strong belief in impact; 2026 Oncology Care Index highlights reimbursement, training, funding barriers.
Hispanic HIV incidence rose 16.8% in antisanctuary counties after the 2018 public charge announcement, relative to baseline counties, a new study found.
A review of randomized clinical trials, nonrandomized trials and case reports suggests that the inflammatory bowel disease risk from treatment with IL-17 inhibitors is low.
From a 95% remission rate in Japan to $81.6 billion in U.S. savings since 2015 — a data-driven look at where biosimilars stand today, and where the gaps remain.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance names interim head after arrest of its president
2
Biosimilars are reshaping pricing and drug development — the numbers behind it
3
Community oncologists are turning to AI, but not all of them use predictive models
4
CMS should test behavior-informed approaches to chronic care
5